---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-030659"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2023-08-30T23:59:59+00:00"
generated_at: "2026-06-11T01:52:42.058561+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Daré Bioscience raises $7.0M in registered direct offering of 10M shares and warrants

## Summary
- Total gross proceeds of $7.0M from sale of 10M shares and warrants at $0.70/unit.
- Warrants exercisable after 6 months at $0.77/share for 5.5 years, with 4.99% ownership limitation.
- Investors include an institutional investor and an affiliate of the licensor of an early stage product candidate.
- Closing expected September 1, 2023; proceeds for general corporate purposes, including clinical trials and R&D.
- Offered under existing S-3 shelf registration statement; prospectus supplement to be filed with SEC.

## SEC filing metadata
- accession: 0001493152-23-030659
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2023-08-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315223030659/0001493152-23-030659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315223030659/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-030659
- JSON: https://secwatch.observer/filing/0001493152-23-030659.json
- Plain text: https://secwatch.observer/filing/0001493152-23-030659.txt

## Key facts
- Material Agreements
  Dare Bioscience, Inc. entered into securities purchase agreement with two institutional investors valued at aggregate gross proceeds to Daré from the offering are expected to be $7.0 million (effective 2023-08-29).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: two institutional investors
  - Value: aggregate gross proceeds to Daré from the offering are expected to be $7.0 million
  - Effective: 2023-08-29
  source text: On August 29, 2023, Daré Bioscience, Inc. (the “Company” or “Daré”) entered into a securities purchase agreement with two institutional investors relating to the purchase and sale in a registered direct offering of an aggregate of (i) 10,000,000 shares of Daré’s common stock, and (ii) warrants to purchase an aggregate of 10,000,000 shares of Daré’s common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401914/000149315223030659/0001493152-23-030659-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.